Notice of Preliminary Results

RNS Number : 7599U

Ergomed plc

02 April 2019

 

 PRESS RELEASE

Notice of Preliminary Results

Guildford, UK - 2 April 2019: Ergomed plc, (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, will announce its Preliminary Results for the full year ending 31 December 2018 on 10 April 2019.

Miroslav Reljanović, Executive Chairman and other members of the management team will host a presentation and conference call for analysts at 08:30am BST on the day of the results at the offices of Numis, 10 Paternoster Sq., London EC4M 7LT.

Enquiries:

Ergomed plc	Tel: [phone]
Miroslav Reljanović (Executive Chairman)
Stuart Jackson (Chief Financial Officer)
Numis Securities Limited	Tel: [phone]
Freddie Barnfield (Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications - for UK enquiries	Tel: [phone]
Chris Gardner / Mary-Jane Elliott	[e-mail]
Matthew Neal / Olivia Manser
MC Services - for Continental European enquiries	Tel: [phone]
Anne Hennecke

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com

 

END

 

 

NORIBMMTMBJMTJL